Incyte target upped to $185 by Barclays
Barclays raised its price target on Incyte (NASDAQ: INCY) to $185.00 (from $135.00) while maintaining a Overweight rating.
Analyst Geoff Meacham raises his PT citing IDO progress and upcoming Olumiant approval. He says his confidence has been increasing with regard to the shifting landscape for epacadostat and upcoming FDA approval of Olumiant.
FY 2017 EPS estimate rises from $0.23 to $0.45, FY 2018 EPS remains at $1.39.